Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies

Patrick Schöffski, Daniel S.W. Tan, Miguel Martín, Mariá Ochoa-De-Olza, John Sarantopoulos, Richard D. Carvajal, Chrisann Kyi, Taito Esaki, Amy Prawira, Wallace Akerley, Filippo De Braud, Rina Hui, Tian Zhang, Ross A. Soo, Michela Maur, Andrew Weickhardt, Jürgen Krauss, Barbara Deschler-Baier, Allen Lau, Tanay S. SamantTyler Longmire, Niladri Roy Chowdhury, Catherine A. Sabatos-Peyton, Nidhi Patel, Radha Ramesh, Tiancen Hu, Ana Carion, Daniel Gusenleitner, Padmaja Yerramilli-Rao, Vasileios Askoxylakis, Eunice L. Kwak, David S. Hong

Hematology & Oncology
Internal Medicine

Research output: Contribution to journal › Article › peer-review

72 Scopus citations

Sort by
Weight
Alphabetically

Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies

Fingerprint

Medicine & Life Sciences